Blenrep Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency
July 20, 2024
July 20, 2024
LONDON, England, July 20 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
- Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
- Trials showed significant progression-free survival benefit and positive overall survival trends for Blenrep combinations versus standard of care
- If approved, Blenrep plus BorDex or PomDex could redefine the relapsed/refracto . . .
* * *
- Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
- Trials showed significant progression-free survival benefit and positive overall survival trends for Blenrep combinations versus standard of care
- If approved, Blenrep plus BorDex or PomDex could redefine the relapsed/refracto . . .